Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer

B. Seruga; H. K. Gan; J. J. Knox

doi:10.3747/co.v16i0.402

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 May 2009

Managing Toxicities and Optimal Dosing of Targeted Drugs in Advanced Kidney Cancer

and

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2009, 16(s1), 52-59;https://doi.org/10.3747/co.v16i0.402

Version Notes

Order Reprints

Abstract

The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.

Keywords:

sunitinib; sorafenib; temsirolimus; toxicity; side effects; management

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents

Review of Guidelines on the Treatment of Metastatic Renal Cell Carcinoma